Vividion advances VVD-214 into Phase 2 with pembrolizumab versus pembrolizumab alone in first-line advanced MSI-high or dMMR colorectal cancer.
Written By: Kalyani Boharapi,
M. Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has initiated a randomized Phase 2 trial of VVD-214, an investigational oral Werner helicase (WRN) inhibitor, in combination with pembrolizumab for first-line treatment of advanced microsatellite instability-high (MSI-high) or deficient mismatch repair (dMMR) colorectal cancer.
The trial will compare the combination with pembrolizumab alone, extending VVD-214’s clinical development into an earlier treatment setting. The company is also evaluating VVD-214 with bevacizumab in a Phase 1b study (NCT06004245) involving patients whose MSI-high or dMMR colorectal cancer progressed after previous treatment.
Colorectal cancer remains a major cause of cancer-related illness and death. MSI-high tumors account for approximately 15% of colorectal cancers, according to the company’s announcement. Although immune checkpoint inhibitors have established a role in this biomarker-defined population, additional treatment strategies could help improve disease control.
WRN Inhibition Targets a Vulnerability in MSI-High Tumors
WRN is a DNA repair enzyme that becomes a potential therapeutic target in cancers with microsatellite instability. MSI-high and dMMR tumors have defects in DNA mismatch repair, creating a biological vulnerability that can make them dependent on WRN for survival.
VVD-214 inhibits WRN, potentially triggering lethal DNA damage in susceptible cancer cells. This synthetic lethality approach could provide a way to selectively target MSI-high or dMMR tumors.
Preliminary Phase 1a (NCT06004245) findings presented at the American Association for Cancer Research 2025 Annual Meeting and subsequently published in Nature Medicine showed initial signs of clinical activity and a tolerability profile that supported further investigation. However, early-phase findings do not establish whether VVD-214 improves the efficacy of pembrolizumab or provides a meaningful clinical benefit.
Trial Will Measure Six-Month Progression-Free Survival
The global Phase 2 study (NCT07811193), plans to enroll approximately 140 patients across clinical sites in around 21 countries spanning North America, Latin America, Europe and Asia.
The primary endpoint is the six-month progression-free survival rate. Secondary endpoints include objective response rate, disease control rate, duration of response, overall survival and safety.
The randomized comparison with pembrolizumab alone will help investigators assess whether adding VVD-214 improves disease control relative to established immunotherapy. Safety findings will also be important because the combination introduces an investigational DNA repair inhibitor into a first-line treatment regimen.
Vividion CEO Aleksandra Rizo said early clinical findings and investigator interest supported expansion into first-line disease. Bayer’s Global Head of Research and Development, Christian Rommel, similarly highlighted the opportunity to evaluate WRN inhibition in a broader patient population.
Clinical Significance Remains to Be Established
The Phase 2 trial represents an important development milestone, but the combination’s clinical value remains uncertain until comparative efficacy and safety data become available. The six-month progression-free survival endpoint will provide an early measure of disease control, while response durability and overall survival will help clarify the longer-term benefit.
The study will also determine whether WRN inhibition adds meaningful activity to pembrolizumab, rather than simply reproducing the effects of existing immunotherapy. No Phase 2 efficacy results have been reported in the announcement.
Beyond VVD-214, Vividion continues to advance early-stage oncology programs, including an oral KEAP1 activator and a RAS-PI3Kα inhibitor. For now, the first-line Phase 2 study provides the next major clinical test of whether targeting WRN can expand treatment options for patients with advanced MSI-high or dMMR colorectal cancer.
Reference
Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase 2 Combination Study in First-Line Patients with Advanced Colorectal Cancer, Vividion Therapeutics, 15 October 2026
Yap, T.A., Fontana, E., Cook, N. et al. Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial. Nat Med (2026). https://doi.org/10.1038/s41591-026-04657-3
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants with Advanced Solid Tumors, ClinicalTrials.gov ID NCT06004245
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.